Form 8-K - Current report:
SEC Accession No. 0001493152-24-014816
Filing Date
2024-04-16
Accepted
2024-04-16 16:05:38
Documents
16
Period of Report
2024-04-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50910
2 ex10-1.htm EX-10.1 205634
3 ex10-2.htm EX-10.2 33640
4 ex10-3.htm EX-10.3 99756
  Complete submission text file 0001493152-24-014816.txt   622412

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE rspi-20240410.xsd EX-101.SCH 3018
6 XBRL LABEL FILE rspi-20240410_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE rspi-20240410_pre.xml EX-101.PRE 22361
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3340
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

EIN.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 24847826
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)